[Antithrombotic properties of the active metabolite of molsidomine, SIN-1].
Molsidomine and its active metabolite SIN-1 were examined in humans and animals for their fibrinolytic and antithrombotic activity. In humans six and eight hours after ingestion of molsidomine retard (8 mg) a marked shortening of euglobulin clot lysis time was observed. Neither molsidomine nor SIN-1 activated fibrinolysis in vitro. In rabbits SIN-1 decreased the size of arterial and venous thrombus. Similar results were obtained with urokinase.
D000818:Animals; D003692:Delayed-Action Preparations; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008981:Molsidomine / Q000031:analogs & derivatives* / Q000494:pharmacology; D011817:Rabbits; D013927:Thrombosis / Q000473:pathology / Q000517:prevention & control*
D003692:Delayed-Action Preparations; C002385:linsidomine; D008981:Molsidomine
Propriétés antithrombotiques du métabolite actif de la molsidomine, le SIN-1.